Drug Repositioning Strategies for the Identification of Novel Therapies for Rheumatic Autoimmune Inflammatory Diseases

Amrie C Grammer; Peter E Lipsky

doi:10.1016/j.rdc.2017.04.010

Drug Repositioning Strategies for the Identification of Novel Therapies for Rheumatic Autoimmune Inflammatory Diseases

Rheum Dis Clin North Am. 2017 Aug;43(3):467-480. doi: 10.1016/j.rdc.2017.04.010.

Authors

Amrie C Grammer¹, Peter E Lipsky²

Affiliations

¹ AMPEL BioSolutions and RILITE Research Institute, 250 West Main Street, Suite 300, Charlottesville, VA 22902, USA. Electronic address: amriegrammer@comcast.net.
² AMPEL BioSolutions and RILITE Research Institute, 250 West Main Street, Suite 300, Charlottesville, VA 22902, USA.

PMID: 28711146
DOI: 10.1016/j.rdc.2017.04.010

Abstract

Rheumatic Autoimmune Inflammatory Diseases such as Sjögren's and lupus lack modern treatments. Less than 5% of drugs approved by the FDA from 2014 to mid-2016 had a RAID indication. Many RAID standard-of-care drugs were repurposed based on serendipitous observations, similarity-of-disease categorization, and/or off-target effects. Recently, drug repurposing has become more intentional, relying on an evolving awareness of molecular underpinnings, as well as a better understanding of drug-target interactions by computational modeling. Understanding mechanisms of disease pathogenesis can be synergistic in identifying new drug candidates and target pathways using unbiased Big-Data repositioning approaches as genomics, PheWAS (disease mechanism-of-action), GWAS and/or epigenetic-profiling.

Keywords: Bioinformatics; Drug repositioning; Drug repurposing; Lupus; Rheumatic autoimmune inflammatory disease (RAID); SLE.

Publication types

Review

MeSH terms

Artificial Intelligence
Autoimmune Diseases / drug therapy*
Autoimmune Diseases / genetics
Computer Simulation
Drug Repositioning / methods*
Drug Therapy, Computer-Assisted
Humans
Models, Molecular
Rheumatic Diseases / drug therapy*
Rheumatic Diseases / genetics